- Published on
Clinical Toxicology — Psoralens
1. Overview
Psoralens are naturally occurring or pharmaceutical photosensitizing compounds belonging to the furocoumarin family. They increase the sensitivity of skin and other tissues to ultraviolet A (UVA) radiation.
Clinically important exposure occurs in two main settings:
- Medication-related exposure: Oral or topical psoralens used in conjunction with UVA light during photochemotherapy.
- Plant-related exposure: Contact with psoralen-containing plant sap, fruit juice, or other botanical preparations followed by sunlight exposure.
The defining toxic effect is phototoxic tissue injury. Exposure to psoralens without subsequent UVA irradiation may produce little immediate toxicity, whereas exposure to both can cause painful erythema, edema, blistering, and extensive burns.
The reaction is often delayed. Skin changes may not become apparent until 24–48 hours after UVA exposure and can continue to worsen over the next day.
Most cases resolve with light avoidance and supportive skin care. Severe phototoxic burns may require specialized wound management or hospitalization.
There is no specific antidote.
The central treatment principle is prevention of additional UVA exposure, including sunlight that passes through window glass.
2. Important psoralen compounds
Methoxsalen
Other names: 8-methoxypsoralen, 8-MOP, xanthotoxin.
Methoxsalen is the best-characterized pharmaceutical psoralen.
It is used with controlled UVA irradiation in a treatment called PUVA photochemotherapy.
Oral methoxsalen has been used for severe psoriasis, while psoralen-based therapy may also be considered for selected other dermatologic conditions.
Some specialized treatments use topical or bath-applied psoralens.
Trioxsalen
Other names: 4,5′,8-trimethylpsoralen, TMP.
Trioxsalen has historically been used for PUVA treatment, including vitiligo.
Availability and clinical use vary by country. It should not be assumed to be a routinely available or preferred contemporary oral treatment.
Bergapten
Other name: 5-methoxypsoralen, 5-MOP.
Bergapten occurs naturally in certain plants and has also been used in specialized photochemotherapy.
Natural furocoumarins
Plants may contain mixtures of psoralen-related compounds.
The clinical phototoxicity of a plant preparation depends on which compounds are present, their concentration, the quantity contacting the skin, and subsequent UVA exposure.
3. Therapeutic uses and PUVA photochemotherapy
PUVA stands for psoralen plus ultraviolet A.
In controlled treatment, a psoralen is administered orally, topically, or through a bath preparation before the patient receives a carefully measured UVA exposure.
PUVA may be used for selected cases of:
- Psoriasis.
- Vitiligo.
- Cutaneous T-cell lymphoma.
- Chronic eczema or other inflammatory skin conditions.
- Certain photodermatoses.
Contemporary position
PUVA remains useful in selected dermatologic disorders but is less commonly chosen for routine psoriasis treatment where safer or more convenient alternatives, such as narrowband UVB phototherapy or systemic medications, are suitable.
Methoxsalen timing
The timing of oral methoxsalen administration depends on the formulation.
Certain rapid-absorption formulations are administered approximately 1.5–2 hours before UVA treatment.
Different formulations can have different absorption and photosensitivity profiles and should not be interchanged without adjusting the phototherapy regimen.
Clinical safety
Therapeutic UVA exposure must be determined by trained clinicians using an established treatment protocol.
Unsupervised oral psoralen use followed by sunlight exposure is unsafe.
4. Natural sources and phytophotodermatitis
Phototoxic furocoumarins are found in certain plants, particularly members of the Rutaceae, Apiaceae, and Moraceae families.
Source
Typical exposure
Lime and certain other citrus fruits
Juice or peel oil on skin followed by sunlight
Fig tree, Ficus carica
Sap or leaves contacting skin
Celery
Plant handling or concentrated plant products
Parsnip
Contact with stems, leaves, or sap
Parsley
Occupational or unusually concentrated exposure
Giant hogweed
Sap contacting skin
Cow parsnip and related plants
Outdoor plant handling
Bergamot oil
Selected cosmetics or fragrances
Not every food or plant in these botanical groups contains equally important quantities of phototoxic furocoumarins.
Lime-associated phototoxicity
A familiar presentation occurs when lime juice contacts the hands during outdoor food or drink preparation.
After sunlight exposure, the skin may develop irregular, drip-shaped, or handprint-like lesions.
This is sometimes called margarita photodermatitis.
Fig-associated injury
Fig sap and certain leaf preparations may produce significant phototoxic burns.
Applying crushed fig leaves or sap to skin as a home remedy is particularly hazardous when followed by sunlight exposure.
Giant hogweed
Giant hogweed sap can cause severe phototoxic skin injury, sometimes involving large areas.
Eye exposure also requires urgent assessment.
Important distinction
Phytophotodermatitis is generally phototoxic rather than allergic. A sufficient combination of furocoumarin exposure and UVA radiation can injure skin even without prior sensitization.
5. Mechanism of toxicity
Psoralens can enter cells and associate with DNA.
When activated by UVA radiation, they may form covalent bonds with DNA, including DNA cross-links.
These reactions interfere with DNA replication and contribute to cellular injury.
Photochemical reactions can also generate reactive oxygen species and damage cellular membranes and proteins.
Phototoxic inflammation
The resulting cellular injury triggers an inflammatory response.
Manifestations include erythema, swelling, pain, and blister formation.
Dose dependence
The severity of injury depends on both psoralen exposure and the amount of UVA radiation reaching the tissue.
Factors that increase risk include:
- Greater psoralen concentration.
- Excessive UVA exposure.
- Fair skin or increased photosensitivity.
- Simultaneous exposure to other photosensitizing agents.
- Failure to protect treated areas.
- Repeated irradiation before a previous reaction becomes apparent.
Important correction
Psoralen toxicity is not limited to direct DNA binding. Oxidative injury and other photochemical mechanisms also contribute.
6. Toxic dose and risk factors
There is no validated universal toxic dose for oral or topical psoralens.
A dose used safely with controlled dermatologic phototherapy may produce severe skin injury if followed by excessive or unplanned sunlight exposure.
Oral ingestion
Nausea and other gastrointestinal symptoms may occur without UVA exposure.
The principal concern after significant ingestion is subsequent generalized photosensitivity.
Topical exposure
A relatively localized exposure to concentrated plant sap or topical psoralen can cause extensive blistering if the affected skin receives sufficient UVA.
Other risk factors
Preexisting photosensitive disorders, abnormal pigmentation, other photosensitizing medications, and inaccurate phototherapy dosing can increase the risk of injury.
Clinical implication
The quantity of psoralen alone does not reliably predict the severity of poisoning without knowing the subsequent UVA exposure.
7. Clinical manifestations
Gastrointestinal effects
Oral methoxsalen may cause nausea, sometimes accompanied by vomiting or abdominal discomfort.
The symptoms are usually mild.
Early cutaneous findings
After UVA activation, patients may develop burning discomfort, tenderness, erythema, and edema.
Delayed phototoxic burns
More severe injury may produce:
- Marked redness.
- Painful swelling.
- Vesicles or large bullae.
- Skin erosion.
- Occasionally ulceration.
The affected skin may resemble a severe sunburn.
Distribution
Systemic oral psoralen exposure can produce widespread photosensitivity in exposed skin.
Topical plant exposure typically causes localized or patterned lesions corresponding to the sites of contact and sunlight exposure.
Linear streaks, splashes, fingerprints, and sharply demarcated areas are characteristic clues.
Pigment changes
Postinflammatory hyperpigmentation is common.
It may persist for months and, in some cases, considerably longer.
Eye effects
Psoralens increase the vulnerability of ocular tissues to UVA injury.
Eye protection is therefore essential during and after oral PUVA treatment.
Long-term concern includes lens injury and cataract formation when appropriate precautions are not followed.
Severe complications
Extensive burns can cause pain, fluid losses, secondary infection, and substantial temporary disability.
Permanent scarring is possible in severe cases, although most uncomplicated lesions heal without significant structural damage.
8. Onset and clinical course
The time course differs from an ordinary thermal burn.
Time from exposure
Possible findings
Shortly after ingestion
Nausea or no symptoms
Following UVA exposure
Photochemical injury begins, often without immediate visible changes
Approximately 24–48 hours
Erythema, pain, swelling, and developing blisters
Approximately 48–72 hours
Peak phototoxic reaction may occur
Following days to weeks
Healing, peeling, and pigment changes
Following months
Persistent hyperpigmentation in some cases
Clinical implication
A patient examined soon after psoralen exposure may have normal skin despite subsequently developing substantial burns.
Absence of visible skin injury during an initial emergency assessment does not exclude delayed phototoxicity.
9. Diagnosis
Diagnosis is primarily clinical.
Exposure history
Determine whether exposure involved oral methoxsalen, another medicinal psoralen, a topical phototherapy preparation, or a naturally occurring plant product.
Ask about the quantity, timing, route of exposure, and subsequent sunlight or artificial UVA exposure.
For phototherapy patients, establish the timing of the medication relative to irradiation, the treatment duration, and whether an excessive dose or equipment error occurred.
Skin examination
Assess the distribution, depth, and extent of injury.
Phototoxic burns are often sharply limited to sun-exposed or plant-contaminated areas.
Differential diagnosis
Consider:
- Ordinary sunburn.
- Thermal or chemical burns.
- Allergic contact dermatitis.
- Other medication-induced phototoxicity.
- Photoallergic dermatitis.
- Porphyria-related photosensitivity.
- Bullous skin disorders.
- Infection or cellulitis.
In children, patterned phytophotodermatitis can occasionally resemble inflicted injury. A careful clinical and exposure history is necessary before drawing conclusions.
10. Investigations
Mild exposure
No routine laboratory investigations are necessary in uncomplicated cases of limited skin involvement.
Severe skin injury
Electrolytes, creatinine, and other tests may be appropriate when extensive burns cause dehydration or systemic complications.
Oral overdose
Routine serum psoralen concentrations are not generally available and do not guide emergency treatment.
After intentional or uncertain overdose, evaluate possible coingestants as clinically indicated.
Burn assessment
Extensive blistering should be assessed for total body surface area, depth, and functional impact.
Ophthalmologic assessment
Eye examination is appropriate for ocular exposure, persistent eye pain, visual symptoms, or other specific concerns.
11. Immediate treatment
Avoiding additional UVA exposure is the most important intervention.
Oral psoralen ingestion
Move the patient to an environment protected from sunlight and other significant UVA sources.
Use appropriate protective clothing and UVA-blocking eyewear.
Consult a poison control center or medical toxicologist for substantial ingestion.
Plant or topical skin exposure
Wash affected skin promptly with soap and water to remove residual sap, juice, or topical preparation.
Remove contaminated clothing.
Early washing may reduce ongoing exposure but cannot reverse photochemical damage that has already occurred.
Eye exposure
Irrigate the eye promptly with water or saline.
Arrange assessment when pain, redness, visual disturbance, or other concerning findings persist.
12. Light avoidance and ocular protection
After oral methoxsalen
U.S. methoxsalen prescribing information directs patients to:
- Avoid sunlight, including sunlight through windows or cloud cover, for at least 8 hours after ingestion.
- Wear suitable UVA-blocking wraparound sunglasses for 24 hours after ingestion during daylight exposure.
- Avoid sunbathing for 48 hours following PUVA treatment.
These are standard labeled precautions for therapeutic use.
After overdose
A substantial or uncertain overdose warrants more conservative photoprotection than routine treatment.
A protected indoor environment and avoidance of significant UVA exposure for at least 24 hours, with longer precautions according to the formulation, dose, and toxicology advice, may be appropriate.
Ocular protection remains essential.
Practical distinction
Protection of the eyes and protection of the skin are separate requirements with different durations.
Ordinary tinted sunglasses are not necessarily adequate; the glasses must provide reliable UVA blocking and sufficient side coverage.
13. Gastrointestinal decontamination
Induced vomiting
Do not induce vomiting with ipecac or other methods.
Although some older methoxsalen labels still advise induced emesis after overdose, this recommendation is inconsistent with contemporary poisoning management.
Gastric lavage
Routine gastric lavage is not recommended.
Activated charcoal
A single dose of activated charcoal may be considered after a substantial recent oral ingestion, provided the airway is protected.
However, evidence supporting a meaningful clinical benefit specifically for psoralen poisoning is limited.
Activated charcoal should not be administered automatically after every ingestion.
Antidote
There is no specific antidote for psoralen poisoning.
14. Management of phototoxic skin injury
Mild reactions
Use cool compresses, appropriate moisturizers, gentle skin cleansing, and analgesics when needed.
Avoid additional UVA exposure.
Inflammatory lesions
Topical corticosteroids may reduce inflammation in selected cases.
Treatment strength and duration should reflect the affected area and clinical severity.
Blistering
Protect blistered areas from further trauma.
Use suitable nonadherent dressings when needed.
Do not routinely rupture intact blisters.
Severe burns
Patients with extensive blistering or deep tissue injury may require specialized burn care.
Assess hydration, pain control, wound infection risk, and functional impairment.
Antibiotics
Antibiotics are not routinely indicated for sterile phototoxic burns.
Treat secondary bacterial infection when clinically suspected or confirmed.
Recovery
The active inflammatory phase generally resolves over days to weeks.
Postinflammatory hyperpigmentation may persist long after the skin has otherwise healed.
15. Long-term risks of therapeutic PUVA
The risk of chronic toxicity differs substantially from the risk after a single accidental ingestion.
Skin cancer
Repeated PUVA exposure is associated with an increased risk of cutaneous squamous cell carcinoma, particularly after high cumulative numbers of treatments.
Risk may persist long after therapy ends.
Basal cell carcinoma and melanoma risks have also been investigated, with associations influenced by cumulative exposure, patient characteristics, and other treatments.
Photoaging
Repeated treatment can contribute to skin wrinkling, dryness, freckling, altered pigmentation, and loss of elasticity.
Eye protection
Appropriate UVA-blocking goggles during treatment and eyewear after oral psoralen administration are important protective measures.
Follow-up
Patients with substantial cumulative PUVA exposure may require long-term dermatologic surveillance for skin cancer.
These risks are related mainly to repeated psoralen-plus-UVA treatment, not ordinary food consumption or a single minor exposure.
16. Interactions and contraindications
Other photosensitizing medications
Additional medications may increase phototoxic or photoallergic reactions.
Examples include selected tetracyclines, fluoroquinolones, thiazide diuretics, phenothiazines, and other photosensitizing drugs.
The risk varies substantially by specific agent.
Photosensitive diseases
Certain porphyrias, lupus-related photosensitivity, xeroderma pigmentosum, and other conditions may make PUVA unsuitable.
Skin cancer history
A history of melanoma or invasive squamous cell carcinoma is a major concern and is included among contraindications in oral methoxsalen labeling.
Eye disorders
Patients without a natural lens, and those with other high-risk ocular conditions, require particular caution.
Pregnancy
Methoxsalen and PUVA are generally avoided during pregnancy because of limited reproductive safety data and the availability of other therapies.
Clinical practice
PUVA should be administered under dermatologic supervision after evaluating contraindications, medication interactions, and the cumulative phototherapy history.
17. Observation and disposition
Minor plant-associated contact
Limited phytophotodermatitis may be managed as an outpatient when pain is controlled, skin involvement is small, and there are no ocular or other complications.
The patient must understand that visible injury may develop after a delay.
Significant oral exposure
Substantial ingestion of a pharmaceutical psoralen requires poison-center assessment and individualized observation.
A normal initial examination does not establish that later UVA-associated injury cannot occur.
Hospital admission
Hospitalization may be appropriate for extensive blistering, severe pain, dehydration, significant ocular injury, or other complications requiring inpatient treatment.
Discharge criteria
Discharge may be appropriate when the patient is clinically stable, the anticipated risk has been assessed, and reliable UVA avoidance and follow-up can be arranged.
A fixed emergency department observation period cannot replace effective light-protection instructions.
18. Prevention and patient education
During PUVA treatment
Take psoralen medications only according to the phototherapy clinic’s instructions.
Do not increase the dose or extend UVA exposure independently.
Avoid tanning beds and unplanned sun exposure.
Use the recommended eye protection and protective clothing.
Report significant redness or burning before any subsequent PUVA session.
During gardening and food preparation
Wash skin promptly after contact with lime juice, fig sap, parsnip, hogweed, or other known photosensitizing plants.
Use gloves and protective clothing when handling hazardous plant material.
Avoid sunlight on contaminated skin.
Household and occupational safety
Workers handling large quantities of furocoumarin-containing plants may benefit from protective gloves, sleeves, face protection, and work-practice changes.
Children
Store pharmaceutical psoralens securely.
Children who develop patterned blistering after outdoor activities may need assessment for plant-associated phototoxicity.
19. Clinical pitfalls
Pitfall
Contemporary correction
Assuming psoralens are highly toxic without light exposure
Their principal serious toxicity requires UVA activation
Assuming normal skin immediately after exposure excludes injury
Burns may emerge 24–48 hours later
Confusing phytophotodermatitis with allergy
It is typically a direct phototoxic reaction
Assuming sunlight through windows is harmless
UVA can penetrate ordinary window glass
Advising simple tinted glasses
Reliable UVA-blocking wraparound eyewear is needed
Using one duration for all photoprotection
Eye and skin protection have different labeled intervals
Inducing vomiting after oral overdose
Do not induce vomiting
Routinely administering charcoal
Use only after individualized assessment
Discharging without delayed-burn precautions
Skin injury may peak at 48–72 hours
Giving antibiotics solely for blistering
Phototoxic burns are not inherently bacterial infections
Assuming food exposure and medicinal PUVA carry identical risks
Concentration, route, and UVA dose determine risk
Ignoring chronic PUVA exposure
Repeated treatment increases skin-cancer risk
Treating severe burns like mild sunburn
Extensive injury may require specialized burn management
Key clinical conclusions
Psoralen poisoning is primarily a photosensitization problem in which the combination of a photoreactive chemical and UVA exposure causes tissue damage.
The greatest immediate danger is delayed, potentially severe skin injury following excessive UVA exposure.
Early washing of contaminated skin, prompt UVA avoidance, and appropriate eye protection are fundamental.
There is no specific antidote. Treatment is supportive and directed toward the severity of skin or ocular injury.
Long-term therapeutic PUVA exposure also requires attention to cumulative skin-cancer risk.